Lowest-Rated StocksLowest-RatedNASDAQ:FUSN Fusion Pharmaceuticals (FUSN) Stock Price, News & Analysis → FW: 234x Gain (From Weiss Ratings) (Ad) Free FUSN Stock Alerts $21.45 -0.04 (-0.19%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$21.43▼$21.5150-Day Range$9.34▼$21.4952-Week Range$2.31▼$21.58Volume468,191 shsAverage Volume1.87 million shsMarket Capitalization$1.82 billionP/E RatioN/ADividend YieldN/APrice Target$20.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Fusion Pharmaceuticals alerts: Email Address Fusion Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingHold2.07 Rating ScoreUpside/Downside5.6% Downside$20.25 Price TargetShort InterestHealthy5.73% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.81Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.46) to ($1.69) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.93 out of 5 starsMedical Sector4735th out of 5,430 stocksBiological Products, Except Diagnostic Industry796th out of 903 stocks 2.0 Analyst's Opinion Consensus RatingFusion Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.07, and is based on 1 buy rating, 13 hold ratings, and no sell ratings.Amount of Analyst CoverageFusion Pharmaceuticals has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.73% of the outstanding shares of Fusion Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverFusion Pharmaceuticals has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Fusion Pharmaceuticals has recently decreased by 6.54%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldFusion Pharmaceuticals does not currently pay a dividend.Dividend GrowthFusion Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FUSN. Previous Next 2.7 News and Social Media Coverage News SentimentFusion Pharmaceuticals has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Fusion Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for FUSN on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Fusion Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fusion Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.75% of the stock of Fusion Pharmaceuticals is held by insiders.Percentage Held by Institutions72.85% of the stock of Fusion Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Fusion Pharmaceuticals are expected to decrease in the coming year, from ($1.46) to ($1.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fusion Pharmaceuticals is -14.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fusion Pharmaceuticals is -14.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFusion Pharmaceuticals has a P/B Ratio of 6.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Fusion Pharmaceuticals Stock (NASDAQ:FUSN)Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.Read More FUSN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FUSN Stock News HeadlinesApril 26, 2024 | msn.comTop 4 Health Care Stocks That May Plunge This MonthApril 26, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Laboratory (LH), Fusion Pharmaceuticals (FUSN) and Integer Holdings (ITGR)May 4, 2024 | Weiss Ratings (Ad)FW: 234x GainThis coin is an essential building block for an ongoing financial revolution of massive dimensions. As a big part of this revolution, the big banks of the world must connect to the blockchain.April 25, 2024 | prnewswire.comFusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim OrderApril 19, 2024 | morningstar.comFusion Pharmaceuticals Inc Ordinary SharesApril 17, 2024 | finance.yahoo.comFusion Pharmaceuticals Inc. (FUSN) Stock Moves -0.09%: What You Should KnowApril 17, 2024 | msn.comTD Cowen Downgrades Fusion Pharmaceuticals (FUSN)April 11, 2024 | finance.yahoo.comFusion Pharmaceuticals Inc. (NASDAQ:FUSN) is definitely on the radar of institutional investors who own 46% of the companyMay 4, 2024 | Weiss Ratings (Ad)FW: 234x GainThis coin is an essential building block for an ongoing financial revolution of massive dimensions. As a big part of this revolution, the big banks of the world must connect to the blockchain.April 9, 2024 | finance.yahoo.comFusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024April 9, 2024 | prnewswire.comFusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024April 3, 2024 | msn.comGenmab Buys ProfoundBio for $1.8B to Boost Oncology PortfolioMarch 28, 2024 | msn.comWhat Fusion Pharmaceuticals (NASDAQ:FUSN) Acquisition Means for InvestorsMarch 26, 2024 | prnewswire.comINVESTIGATION: The M&A Class Action Firm Announces an Investigation of Fusion Pharmaceuticals Inc. - FUSNMarch 20, 2024 | msn.comFUSN Stock Earnings: Fusion Pharmaceuticals Misses EPS for Q4 2023March 20, 2024 | markets.businessinsider.comFusion Pharmaceuticals: Hold Rating Justified Amid Acquisition and Radiopharmaceutical Market DynamicsMarch 20, 2024 | stockhouse.comKuehn Law Encourages DRQ, EVBG, FREE, and FUSN Investors to Contact Law FirmMarch 20, 2024 | finance.yahoo.comFusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program UpdatesMarch 20, 2024 | markets.businessinsider.comUnveiling 11 Analyst Insights On Fusion PharmaceuticalsMarch 19, 2024 | businesswire.comFUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSNMarch 19, 2024 | businesswire.comFUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSNMarch 19, 2024 | finance.yahoo.comHeard on the Street: Pharma Goes Radioactive as AstraZeneca Announces Fusion DealMarch 19, 2024 | finance.yahoo.comSuper Micro, XPeng, AstraZeneca: Trending tickersMarch 19, 2024 | finance.yahoo.comFusion Rockets 97%, As Radiopharmaceuticals Space Sparks On $2 Billion AstraZeneca TakeoverMarch 19, 2024 | financialpost.comAstraZeneca to buy Canadian cancer treatment developer Fusion PharmaceuticalsMarch 19, 2024 | proactiveinvestors.comAstraZeneca is paying $2.4bn for Fusion Pharmaceuticals - but actually is it gettingMarch 19, 2024 | investorplace.comWhy Is Fusion Pharmaceuticals (FUSN) Stock Up 101% Today?See More Headlines Receive FUSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/20/2024Today5/03/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:FUSN CUSIPN/A CIK1805890 Webfusionpharma.com Phone289-799-0891FaxN/AEmployees101Year FoundedN/APrice Target and Rating Average Stock Price Target$20.25 High Stock Price Target$24.00 Low Stock Price Target$15.00 Potential Upside/Downside-5.6%Consensus RatingHold Rating Score (0-4)2.07 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($1.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-94,900,000.00 Net Margins-4,136.55% Pretax Margin-4,550.77% Return on Equity-46.59% Return on Assets-35.34% Debt Debt-to-Equity Ratio0.16 Current Ratio15.01 Quick Ratio15.01 Sales & Book Value Annual Sales$2.07 million Price / Sales879.35 Cash FlowN/A Price / Cash FlowN/A Book Value$3.07 per share Price / Book6.99Miscellaneous Outstanding Shares84,860,000Free Float78,288,000Market Cap$1.82 billion OptionableOptionable Beta-0.69 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. John F. Valliant Ph.D. (Age 53)Founder, CEO & Director Comp: $911.34kDr. Christopher Paul Leamon Ph.D. (Age 58)Chief Scientific Officer Ms. Amanda CraySenior Director of Investor Relations & Corporate CommunicationsMs. Maria D. Stahl (Age 53)Chief Legal Officer Mr. Eric S. Hoffman Ph.D. (Age 54)Senior Vice President of Business Development Dr. Cara Ferreira Ph.D.Chief of StaffDr. Joanne SchindlerExecutive Vice President of Medical Director & Clinical DevelopmentMore ExecutivesKey CompetitorsTwist BioscienceNASDAQ:TWSTRecursion PharmaceuticalsNASDAQ:RXRXBeam TherapeuticsNASDAQ:BEAMGinkgo BioworksNYSE:DNASana BiotechnologyNASDAQ:SANAView All CompetitorsInstitutional OwnershipFifth Lane Capital LPBought 25,000 shares on 5/2/2024Ownership: 0.000%Privium Fund Management B.V.Bought 109,408 shares on 4/30/2024Ownership: 0.296%China Universal Asset Management Co. Ltd.Bought 5,544 shares on 4/29/2024Ownership: 0.016%Equitec Proprietary Markets LLCBought 157,700 shares on 4/26/2024Ownership: 0.000%Wellington Management Group LLPBought 744,474 shares on 3/5/2024Ownership: 1.028%View All Institutional Transactions FUSN Stock Analysis - Frequently Asked Questions Should I buy or sell Fusion Pharmaceuticals stock right now? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fusion Pharmaceuticals in the last year. There are currently 13 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" FUSN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FUSN, but not buy additional shares or sell existing shares. View FUSN analyst ratings or view top-rated stocks. What is Fusion Pharmaceuticals' stock price target for 2024? 14 Wall Street analysts have issued 12 month price objectives for Fusion Pharmaceuticals' stock. Their FUSN share price targets range from $15.00 to $24.00. On average, they expect the company's share price to reach $20.25 in the next year. This suggests that the stock has a possible downside of 5.6%. View analysts price targets for FUSN or view top-rated stocks among Wall Street analysts. How have FUSN shares performed in 2024? Fusion Pharmaceuticals' stock was trading at $9.61 on January 1st, 2024. Since then, FUSN shares have increased by 123.2% and is now trading at $21.45. View the best growth stocks for 2024 here. Are investors shorting Fusion Pharmaceuticals? Fusion Pharmaceuticals saw a decline in short interest in April. As of April 15th, there was short interest totaling 4,860,000 shares, a decline of 6.5% from the March 31st total of 5,200,000 shares. Based on an average daily trading volume, of 2,140,000 shares, the short-interest ratio is presently 2.3 days. View Fusion Pharmaceuticals' Short Interest. When is Fusion Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our FUSN earnings forecast. How were Fusion Pharmaceuticals' earnings last quarter? Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) released its quarterly earnings results on Wednesday, March, 20th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.05. Fusion Pharmaceuticals had a negative trailing twelve-month return on equity of 46.59% and a negative net margin of 4,136.55%. What ETFs hold Fusion Pharmaceuticals' stock? ETFs with the largest weight of Fusion Pharmaceuticals (NASDAQ:FUSN) stock in their portfolio include ProShares Merger ETF (MRGR) and IQ Merger Arbitrage ETF (MNA).Tema Oncology ETF (CANC). What other stocks do shareholders of Fusion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fusion Pharmaceuticals investors own include Overstock.com (OSTK), U.S. Xpress Enterprises (USX), Camping World (CWH), DocuSign (DOCU), Pfizer (PFE), Pure Storage (PSTG), CrowdStrike (CRWD), Livongo Health (LVGO), NVIDIA (NVDA) and OPKO Health (OPK). When did Fusion Pharmaceuticals IPO? Fusion Pharmaceuticals (FUSN) raised $126 million in an initial public offering on Friday, June 26th 2020. The company issued 8,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Fusion Pharmaceuticals' major shareholders? Fusion Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Privium Fund Management B.V. (0.30%), Equitec Proprietary Markets LLC (0.00%), Fifth Lane Capital LP (0.00%) and China Universal Asset Management Co. Ltd. (0.02%). Insiders that own company stock include John Valliant and Steven Gannon. View institutional ownership trends. How do I buy shares of Fusion Pharmaceuticals? Shares of FUSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FUSN) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldUrgent Nvidia WarningAltimetryAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldGold ManiaStansberry ResearchThe Gold Grab of the CenturyColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fusion Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.